The list price for tirzepatide (Mounjaro) in the United States varies depending on the dosage and whether it is obtained through a pharmacy or a doctor's office. For example, a 4-week supply of Mounjaro at a dosage of 5 mg/0.5 mL can cost around $1,009.78, while higher dosages, such as 10 mg/0.5 mL or 15 mg/0.5 mL, may have similar pricing for a 4-week supply. These prices are based on cash prices and do not reflect potential discounts or insurance coverage. [1]
How much does tirzepatide cost with insurance?
The cost of tirzepatide can be significantly reduced for insured individuals. For example, eligible patients with commercial insurance can sometimes obtain a Mounjaro savings card, which may lower their out-of-pocket cost to as little as $25 for a 1-month or 3-month supply, depending on the terms of the program and formulary placement. [1]
What is the retail price of tirzepatide?
The retail price for tirzepatide, marketed as Mounjaro, generally falls around $1,000 for a 4-week supply, with variations based on specific dosage strengths. This cash price is before any insurance benefits or discount programs are applied. [1]
Are there programs to help lower the cost of tirzepatide?
Yes, patient assistance programs and savings cards are available to help reduce the cost of tirzepatide. For instance, Eli Lilly, the manufacturer of Mounjaro, offers a Mounjaro Savings Card that can reduce the cost for eligible commercially insured patients. [1]
When does tirzepatide's patent expire?
The patent landscape for tirzepatide is complex, involving multiple patents covering different aspects of the drug, including its composition of matter, methods of use, and manufacturing processes. Some of these patents may expire in the mid-2030s, while others could extend into the 2040s or beyond, depending on their specific coverage and any potential extensions. [2]
Who manufactures tirzepatide?
Tirzepatide is manufactured by Eli Lilly and Company. It is marketed under the brand name Mounjaro for type 2 diabetes and under the brand name Zepbound for chronic weight management. [1, 3]
What is the difference between Mounjaro and Zepbound?
Mounjaro and Zepbound both contain the active ingredient tirzepatide. Mounjaro is approved for the treatment of type 2 diabetes, while Zepbound is approved for chronic weight management in individuals with obesity or overweight with at least one weight-related condition. The prescribing indication is the primary distinction between the two brand names. [3]
What are the potential side effects of tirzepatide?
Common side effects of tirzepatide can include nausea, vomiting, diarrhea, abdominal pain, decreased appetite, and constipation. More serious but less common side effects may include pancreatitis, gallbladder problems, kidney problems, serious allergic reactions, and diabetic retinopathy complications. [4]
How does tirzepatide work?
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. By activating these receptors, it helps to lower blood glucose levels, promote weight loss, and improve insulin sensitivity. [4]
Sources:
[1] https://www.goodrx.com/mounjaro
[2] https://drugpatentwatch.com/drugs/tirzepatide
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10376595/
[4] https://www.mayoclinic.org/drugs-supplements/tirzepatide-injectable-drug/side-effects/drh-20501968